Applied Therapeutics (APLT)
(Delayed Data from NSDQ)
$5.24 USD
-0.11 (-2.06%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $5.24 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$5.24 USD
-0.11 (-2.06%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $5.24 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth C Momentum F VGM
Zacks News
Here's Why You Should Retain Universal Health (UHS) Stock Now
by Zacks Equity Research
Increased admissions at both of its operating segments, constant initiatives to bolster its care network and adequate cash generation abilities are likely to drive Universal Health (UHS).
Encompass Health's (EHC) Nationwide Hospital Count Rises to 147
by Zacks Equity Research
Encompass Health (EHC) opens a 60-bed inpatient rehabilitation hospital in Illinois, sustaining its aim to offer enhanced rehabilitation services throughout the United States.
Molina Healthcare (MOH) Up 32% in a Year: Is More Upside Left?
by Zacks Equity Research
Continued revenue growth, well-performing Medicaid and Medicare businesses, expense saving initiatives and solid cash balance continue to drive Molina Healthcare (MOH).
Applied Therapeutics Inc. (APLT) Upgraded to Buy: Here's Why
by Zacks Equity Research
Applied Therapeutics Inc. (APLT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Applied Therapeutics Inc. (APLT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Applied Therapeutics Inc. (APLT) closed at $22.86 in the latest trading session, marking a -0.95% move from the prior day.
Applied Therapeutics Inc. (APLT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Applied Therapeutics Inc. (APLT) closed at $20.02 in the latest trading session, marking a +0.05% move from the prior day.
Applied Therapeutics Inc. (APLT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Applied Therapeutics Inc. (APLT) closed at $24.36, marking a +1.71% move from the previous day.
New Strong Sell Stocks for August 17th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Applied Therapeutics Inc. (APLT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Applied Therapeutics Inc. (APLT) closed at $25.93, marking a +0.5% move from the previous day.
Ultragenyx (RARE) Loss Narrows Y/Y & Revenues Beat Estimates
by Zacks Equity Research
Ultragenyx (RARE) reports a narrower-than-expected loss in the second quarter of 2020 and beats sales estimates.
Alexion (ALXN) Beats on Q2 Earnings & Sales, Ups '20 Guidance
by Zacks Equity Research
Alexion (ALXN) beats on earnings and sales in the second quarter of 2020.
Dr. Reddy's (RDY) Q1 Earnings Decline Y/Y, Sales Increase
by Zacks Equity Research
Dr. Reddy's (RDY) earnings and revenues decline year over year in first-quarter fiscal 2021.
Alkermes' (ALKS) Q2 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Alkermes' (ALKS) earnings decline year over year in the second quarter of 2020.
Applied Therapeutics Inc. (APLT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Applied Therapeutics Inc. (APLT) closed the most recent trading day at $25.74, moving +1.74% from the previous trading session.
What to Expect for Applied Therapeutics (APLT) Q2 Earnings
by Zacks Equity Research
During Applied Therapeutics' (APLT) upcoming Q2 earnings call, investor focus will be on the company's progress with its novel pipeline candidates targeting areas of high unmet medical need.
Zacks.com featured highlights include: Applied Therapeutics, Green Brick Partners, Frequency Therapeutics and Kelly Services
by Zacks Equity Research
Zacks.com featured highlights include: Applied Therapeutics, Green Brick Partners, Frequency Therapeutics and Kelly Services
LogicBio Therapeutics (LOGC) Catches Eye: Stock Jumps 7.1%
by Zacks Equity Research
LogicBio Therapeutics (LOGC) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
4 Stocks to Make the Most of New Analyst Coverage
by Shrabana Mukherjee
Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.
Applied Therapeutics Inc. (APLT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Applied Therapeutics Inc. (APLT) closed the most recent trading day at $28.36, moving +0.32% from the previous trading session.
Moderna (MRNA) in Focus: Stock Moves 6.9% Higher
by Zacks Equity Research
Moderna (MRNA) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Principia Biopharma (PRNB) Jumps: Stock Rises 6.8%
by Zacks Equity Research
Principia Biopharma (PRNB) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
BeiGene (BGNE) in Focus: Stock Moves 8.7% Higher
by Zacks Equity Research
BeiGene (BGNE) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Is Applied Therapeutics (APLT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (APLT) Outperforming Other Medical Stocks This Year?
Prothena (PRTA) Looks Good: Stock Adds 10.6% in Session
by Zacks Equity Research
Prothena (PRTA) saw a big move last session, as its shares jumped nearly 11% on the day, amid huge volumes.
89bio (ETNB) Jumps: Stock Rises 6.9%
by Zacks Equity Research
89bio (ETNB) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.